Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro Inc. (NASDAQ: CLPT) is a leader in MRI-guided neurosurgical navigation systems and targeted therapeutic delivery solutions for neurological disorders. This page serves as the definitive source for official company announcements, regulatory updates, and strategic developments in precision neurosurgery and cell/gene therapy delivery.
Access real-time updates on CLPT's innovative medical devices, including the SmartFlow® Cannula and Prism® Laser Therapy System. Stay informed about FDA clearances, biopharma partnerships, clinical trial milestones, and financial disclosures that demonstrate the company's progress in advancing minimally invasive neurological treatments.
Key updates include earnings reports, product launch announcements, research collaborations with academic institutions, and expansion of global clinical sites. Our curated news collection enables investors and healthcare professionals to track CLPT's role in enabling next-generation therapies for Parkinson's disease, brain tumors, and rare genetic conditions.
Bookmark this page for streamlined access to ClearPoint Neuro's latest achievements in neurosurgical navigation technology and therapeutic delivery systems. Check regularly for verified updates on regulatory approvals, intellectual property developments, and strategic initiatives shaping the future of precision neurology.
ClearPoint Neuro (Nasdaq: CLPT), a global therapy-enabling platform company focused on brain navigation and delivery, has announced its participation in the B. Riley Securities 2023 Institutional Investor Conference. The company's management team is scheduled to present on Wednesday, May 24, 2023, at 8:15 a.m. Pacific Time.
This conference provides an opportunity for ClearPoint Neuro to showcase its innovative technologies and business strategies to institutional investors. As a leader in brain-focused therapies, the company's presentation is likely to generate significant interest among attendees and potential investors in the medical technology sector.
ClearPoint Neuro will showcase its innovative solutions, including the SmartFlow cannula and Maestro Brain Model, at the 2023 American Association of Neurological Surgeons (AANS) Annual Meeting in Los Angeles from April 21 to 23. The Maestro Brain Model, recently gaining FDA clearance, facilitates precise interventions under MRI guidance. ClearPoint also highlights its Prism Neuro Laser Therapy System, currently in limited release, aiding in the treatment of brain tumors and epilepsy. ClearPoint aims to emerge as a leading provider for neurosurgeons with advanced technologies designed for improved patient outcomes. Over 6,000 procedures have utilized ClearPoint’s offerings, which are strategically partnered with over 50 companies and institutions worldwide.
ClearPoint Neuro (NASDAQ: CLPT) has entered an exclusive agreement with NE Scientific to develop a GPU-accelerated software for modeling drug infusions using the ClearPoint SmartFlow® cannula. This software aims to simulate patient-specific infusion in real time, optimizing infusion parameters like target points, flow rate, and leakage control. The innovative solution is expected to enhance the precision of neurosurgical procedures by allowing surgeons to visualize and quantify therapeutic agent distribution before the actual procedure.
With over 6,000 procedures performed, ClearPoint's navigation system is already well-established, being FDA cleared and CE-marked. This new collaboration could significantly reduce variability in drug delivery, potentially improving outcomes in clinical trials.
FAQ
What is the current stock price of Clearpoint Neuro (CLPT)?
What is the market cap of Clearpoint Neuro (CLPT)?
